KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Accumulated Expenses (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Accumulated Expenses for 17 consecutive years, with $172.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 38.73% to $172.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.3 million through Dec 2025, up 38.73% year-over-year, with the annual reading at $172.3 million for FY2025, 38.73% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $172.3 million at Bio-Rad Laboratories, down from $182.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $277.0 million in Q4 2021, with the low at $124.2 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $175.0 million, with a median of $173.1 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses fell 29.68% in 2022, then skyrocketed 38.73% in 2025.
  • Over 5 years, Accumulated Expenses stood at $277.0 million in 2021, then fell by 29.68% to $194.8 million in 2022, then dropped by 28.18% to $139.9 million in 2023, then fell by 11.22% to $124.2 million in 2024, then soared by 38.73% to $172.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $172.3 million, $182.8 million, and $157.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.